Palvella Therapeutics Inc. Ordinary Shares PVLA 深 沪
已收盘 12-19 16:00:00 美东时间
100.13
+3.890
+4.04%
华盛通- 最 高112.00
- 今 开96.79
- 成交量 34.53万股
- 最 低 84.25
- 昨 收 96.24
- 总市值 0
- 52周最高 112.00
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 11.17
- 委 比 -69.41%
- 总股本 --
- 历史最高 112.00
- 量 比 0
- 振 幅 28.83%
- 历史最低 11.17
- 每 手 1
- 风险率 24.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palvella: 73% Improved In Phase 2 Study Of Skin Condition Treatment
Palvella Therapeutics reports Phase 2 data showing 73% improvement with QTORIN rapamycin gel in cutaneous venous malformations.
12-16 00:50
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
Palvella Therapeutics successfully completed the Phase 3 SELVA trial of QTORIN™ rapamycin for microcystic lymphatic malformations, enrolling 51 subjects exceeding the 40-target. Top-line data expected in Q1 2026.
06-23 11:30
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
Palvella Therapeutics has secured a new U.S. patent (No. 12,329,748) for its lead product QTORIN™ rapamycin, reinforcing exclusivity through 2038. The patent covers its anhydrous formulation and methods targeting rare skin diseases, supported by orphan drug designation and seven-year exclusivity.
06-18 11:30
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
Palvella Therapeutics receives $2.6 million FDA grant for its Phase 3 SELVA trial of QTORIN™ rapamycin to treat microcystic lymphatic malformations, with top-line data expected in Q1 2026.
06-09 11:30
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
Ashley Kline appointed as Palvella Therapeutics' Chief Commercial Officer to lead QTORIN™ launch targeting rare genetic skin diseases. Kline previously achieved $500M+ U.S. sales for Oxervate® in rare disease.
05-27 12:00
Scotiabank Initiates Coverage On Palvella Therapeutics with Sector Outperform Rating, Announces Price Target of $50
Scotiabank analyst Louise Chen initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Sector Outperform rating and announces Price Target of $50.
03-08 06:29
